KW-6356
Total Payments
$1.4M
Transactions
34
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $723,246 | 27 | 3 |
| 2019 | $629,119 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 31 | 99.6% |
| Consulting Fee | $5,625 | 3 | 0.4% |
Payments by Type
Research
$1.3M
31 transactions
General
$5,625
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356 | Kyowa Kirin Pharmaceutical Development, Inc | $717,621 | 0 |
| Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of 14C-KW-6356 | Kyowa Kirin Pharmaceutical Development, Inc | $629,119 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 3
- Transactions 34
About KW-6356
KW-6356 is a drug associated with $1.4M in payments to 3 healthcare providers, recorded across 34 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin Pharmaceutical Development, Inc.
Payment data is available from 2019 to 2020. In 2020, $723,246 was paid across 27 transactions to 3 doctors.
The most common payment nature for KW-6356 is "Unspecified" ($1.3M, 99.6% of total).
KW-6356 is associated with 2 research studies, including "Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356" ($717,621).